BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35920832)

  • 1.
    Zhang M; Li J; Lin W; Qi L; Yao C; Zheng Z; Chen C; Duan S; Qi Y
    Genet Test Mol Biomarkers; 2022; 26(7-8):360-374. PubMed ID: 35920832
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypoxic-stabilized EPAS1 proteins transactivate DNMT1 and cause promoter hypermethylation and transcription inhibition of EPAS1 in non-small cell lung cancer.
    Xu XH; Bao Y; Wang X; Yan F; Guo S; Ma Y; Xu D; Jin L; Xu J; Wang J
    FASEB J; 2018 Jun; ():fj201700715. PubMed ID: 29920222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FHIT promoter methylation status, low protein and high mRNA levels in patients with non-small cell lung cancer.
    Czarnecka KH; Migdalska-Sęk M; Domańska D; Pastuszak-Lewandoska D; Dutkowska A; Kordiak J; Nawrot E; Kiszałkiewicz J; Antczak A; Brzeziańska-Lasota E
    Int J Oncol; 2016 Sep; 49(3):1175-84. PubMed ID: 27572663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells.
    Zhen Q; Liu JF; Liu JB; Wang RF; Chu WW; Zhang YX; Tan GL; Zhao XJ; Lv BL
    Cancer Biol Ther; 2015; 16(4):549-57. PubMed ID: 25831463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TMEM196 hypermethylation as a novel diagnostic and prognostic biomarker for lung cancer.
    Liu WB; Han F; Huang YS; Chen HQ; Chen JP; Wang DD; Jiang X; Yin L; Cao J; Liu JY
    Mol Carcinog; 2019 Apr; 58(4):474-487. PubMed ID: 30536447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.
    Mastoraki S; Balgkouranidou I; Tsaroucha E; Klinakis A; Georgoulias V; Lianidou E
    Mol Oncol; 2021 Sep; 15(9):2412-2422. PubMed ID: 33159839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of apoptosis-associated speck-like protein containing a CARD gene promoter methylation in resectable non-small-cell lung cancer.
    Zhang Z; Tan S; Zhang L
    Clin Lung Cancer; 2006 Jul; 8(1):62-5. PubMed ID: 16870048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXP family DNA methylation correlates with immune infiltration and prognostic value in NSCLC.
    Hu DM; Zhang WD; Shi ZE; Zhang MY; Li R; Wang QX; Ji XL; Qu YQ
    Front Genet; 2022; 13():937069. PubMed ID: 36160018
    [No Abstract]   [Full Text] [Related]  

  • 9. MiR-182-5p promotes the Metastasis and Epithelial-mesenchymal Transition in Non-small Cell Lung Cancer by Targeting EPAS1.
    Yang W; Yin Y; Bi L; Wang Y; Yao J; Xu L; Jiao L
    J Cancer; 2021; 12(23):7120-7129. PubMed ID: 34729113
    [No Abstract]   [Full Text] [Related]  

  • 10. Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer.
    Zhang X; Yang X; Wang J; Liang T; Gu Y; Yang D
    Int J Clin Exp Pathol; 2015; 8(9):11452-7. PubMed ID: 26617874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.
    Grasse S; Lienhard M; Frese S; Kerick M; Steinbach A; Grimm C; Hussong M; Rolff J; Becker M; Dreher F; Schirmer U; Boerno S; Ramisch A; Leschber G; Timmermann B; Grohé C; Lüders H; Vingron M; Fichtner I; Klein S; Odenthal M; Büttner R; Lehrach H; Sültmann H; Herwig R; Schweiger MR
    Genome Med; 2018 Jul; 10(1):55. PubMed ID: 30029672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter hypermethylation of the p16 and Wif-1 genes as an independent prognostic marker in stage IA non-small cell lung cancers.
    Yoshino M; Suzuki M; Tian L; Moriya Y; Hoshino H; Okamoto T; Yoshida S; Shibuya K; Yoshino I
    Int J Oncol; 2009 Nov; 35(5):1201-9. PubMed ID: 19787276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer.
    Liu S; Chen X; Chen R; Wang J; Zhu G; Jiang J; Wang H; Duan S; Huang J
    Oncotarget; 2017 May; 8(22):36354-36367. PubMed ID: 28422739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer.
    Balgkouranidou I; Chimonidou M; Milaki G; Tsarouxa EG; Kakolyris S; Welch DR; Georgoulias V; Lianidou ES
    Br J Cancer; 2014 Apr; 110(8):2054-62. PubMed ID: 24642624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA hypermethylation of microRNA-34b/c has prognostic value for stage Ⅰ non-small cell lung cancer.
    Wang Z; Chen Z; Gao Y; Li N; Li B; Tan F; Tan X; Lu N; Sun Y; Sun J; Sun N; He J
    Cancer Biol Ther; 2011 Mar; 11(5):490-6. PubMed ID: 21383543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
    BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SNCA correlates with immune infiltration and serves as a prognostic biomarker in lung adenocarcinoma.
    Zhang X; Wu Z; Ma K
    BMC Cancer; 2022 Apr; 22(1):406. PubMed ID: 35421944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer.
    Tang X; Khuri FR; Lee JJ; Kemp BL; Liu D; Hong WK; Mao L
    J Natl Cancer Inst; 2000 Sep; 92(18):1511-6. PubMed ID: 10995806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer.
    Saito K; Kawakami K; Matsumoto I; Oda M; Watanabe G; Minamoto T
    Clin Cancer Res; 2010 Apr; 16(8):2418-26. PubMed ID: 20371677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.